It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Wash-sale considerations when replacing dividend ETF protect your tax position. This guide outlines rule basics, look-back periods, and compliant practices.
13,645 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
A fresh pullback can create smart entry points. This guide highlights my top 3 financial stocks after latest market p...
Bitcoin volatility remains headline news, but one historically cheap stock in gold mining delivers tangible cash flow...
Bank of America just delivered a standout quarter with revenue and earnings beating estimates and a solid return on t...
As 2026 unfolds, REITs offer liquidity and steady income in a rate-sensitive environment. This report highlights the ...
Income-focused investors are turning to a small group of high-yield energy names that offer cash-flow visibility and ...
Apple accelerates its cash-return program with a fresh buyback authorization and a dividend bump, underscoring a disc...
The YieldMax NVDA Option Income Strategy ETF has drawn attention for its high advertised yield, but market dynamics a...
EWZ’s semi-annual payouts are highly dependent on Petrobras and Vale, delivering big checks in buoyant commodity mark...
A long-running trend shows the sector wall street calls defensive, led by utilities, delivering returns that outpace ...
As technology stocks dominate the market, smart money fleeing tech may seek ballast in Johnson & Johnson. This articl...
Inflation remains a headwind for cash savers. This report outlines a three-ETF approach designed for someone who’s ne...